[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112021025795A2 - Terapia de combinação com bloqueio da semaforina-4d (sema4d) e terapia com dc1 - Google Patents

Terapia de combinação com bloqueio da semaforina-4d (sema4d) e terapia com dc1

Info

Publication number
BR112021025795A2
BR112021025795A2 BR112021025795A BR112021025795A BR112021025795A2 BR 112021025795 A2 BR112021025795 A2 BR 112021025795A2 BR 112021025795 A BR112021025795 A BR 112021025795A BR 112021025795 A BR112021025795 A BR 112021025795A BR 112021025795 A2 BR112021025795 A2 BR 112021025795A2
Authority
BR
Brazil
Prior art keywords
therapy
sema4d
blockade
semaphorin
combination therapy
Prior art date
Application number
BR112021025795A
Other languages
English (en)
Inventor
Brian Czerniecki
Elizabeth Evans
Krithika Kodumudi
Original Assignee
H Lee Moffitt Cancer Center And Res Institute Inc A Florida Non Profit Corporation
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Center And Res Institute Inc A Florida Non Profit Corporation, Vaccinex Inc filed Critical H Lee Moffitt Cancer Center And Res Institute Inc A Florida Non Profit Corporation
Publication of BR112021025795A2 publication Critical patent/BR112021025795A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

terapia de combinação com bloqueio da semaforina4d (sema4d) e terapia com dc1. são divulgados composições e métodos que compreendem a administração de células dendríticas pulsadas e um inibidor de uma molécula imunorreguladora para o tratamento de câncer.
BR112021025795A 2019-06-21 2020-06-19 Terapia de combinação com bloqueio da semaforina-4d (sema4d) e terapia com dc1 BR112021025795A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962865027P 2019-06-21 2019-06-21
PCT/US2020/038719 WO2020257640A1 (en) 2019-06-21 2020-06-19 Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy

Publications (1)

Publication Number Publication Date
BR112021025795A2 true BR112021025795A2 (pt) 2022-02-01

Family

ID=71575807

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025795A BR112021025795A2 (pt) 2019-06-21 2020-06-19 Terapia de combinação com bloqueio da semaforina-4d (sema4d) e terapia com dc1

Country Status (11)

Country Link
US (2) US11660330B2 (pt)
EP (1) EP3986446A1 (pt)
JP (1) JP7579284B2 (pt)
KR (1) KR20220044490A (pt)
CN (1) CN114364399A (pt)
AU (1) AU2020297592A1 (pt)
BR (1) BR112021025795A2 (pt)
CA (1) CA3142777A1 (pt)
IL (1) IL288779A (pt)
MX (1) MX2021015970A (pt)
WO (1) WO2020257640A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024159105A1 (en) * 2023-01-26 2024-08-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of treating cancer comprising administration of intratumoral dcs in combination with systemic igg monoclonal antibody
WO2024159101A1 (en) * 2023-01-26 2024-08-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for identifying disseminated cancer cells in breast cancer patients

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (pt) 1968-10-17 1970-08-24
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
DK0703925T3 (da) 1993-06-03 1999-12-06 Therapeutic Antibodies Inc Fremstilling af antistoffragmenter
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
FR2765243B1 (fr) 1997-06-30 1999-07-30 Usinor Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
NZ596136A (en) 2009-05-08 2013-12-20 Vaccinex Inc Anti-cd100 antibodies and methods for using the same
CN105492016A (zh) 2013-06-25 2016-04-13 瓦西尼斯公司 脑信号蛋白-4d抑制分子与免疫调节治疗联用以抑制肿瘤生长和转移的应用
JP2017512493A (ja) * 2014-03-14 2017-05-25 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 癌のｃｄ４＋ｔヘルパー１型応答の監視方法および免疫回復
WO2016190940A1 (en) 2015-05-22 2016-12-01 Czerniecki Brian J Manufacturing multi-dose injection ready dendritic cell vaccines
CA2955445A1 (en) * 2014-07-17 2016-01-21 Brian J. Czerniecki Manufacturing of multi-dose injection ready dendritic cell vaccines and combination therapy for blocking her2 and her3

Also Published As

Publication number Publication date
CA3142777A1 (en) 2020-12-24
WO2020257640A1 (en) 2020-12-24
KR20220044490A (ko) 2022-04-08
US20200397881A1 (en) 2020-12-24
AU2020297592A1 (en) 2022-01-06
JP2022537453A (ja) 2022-08-25
JP7579284B2 (ja) 2024-11-07
EP3986446A1 (en) 2022-04-27
US20240050544A1 (en) 2024-02-15
MX2021015970A (es) 2022-04-06
US11660330B2 (en) 2023-05-30
CN114364399A (zh) 2022-04-15
IL288779A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CL2018000803A1 (es) Composiciones y métodos para inhibir la expresión génica de lpa.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
BR112015016466A2 (pt) método para o tratamento de câncer baseado no estado de mutação de k-ras
BR112017013599A2 (pt) composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras.
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112017027954A2 (pt) métodos de tratamento de tumores de célula epitelioide
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
BR112018007447A2 (pt) terapia de combinação para tratamento de malignidades
BR112013026494A2 (pt) composto, composição farmacêutica, método para tratar condição
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
BR112021025795A2 (pt) Terapia de combinação com bloqueio da semaforina-4d (sema4d) e terapia com dc1
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
BR112018072339A2 (pt) tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados
BR112019006329A2 (pt) métodos de tratamento de câncer do trato biliar
UY37800A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
BR112018068027A2 (pt) método para tratar câncer em um paciente e composição farmacêutica
BR112022006476A2 (pt) Oligonucleotídeos com análogos de nucleosídeos
CO2022014499A2 (es) Moduladores de nlrp3
BR112023000654A2 (pt) Composto de pirazolopirimidina usado como inibidor de atr quinase